Skip to content

Evaluation of Atomoxetine efficacy on Freezing of gait in patient with Parkinson

Evaluation of Atomoxetine efficacy on Freezing of gait in patient with Parkinson

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20211008052695N1
Enrollment
32
Registered
2021-11-17
Start date
2021-09-23
Completion date
Unknown
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson disease. Secondary parkinsonism, unspecified

Interventions

Intervention 1: Intervention group: Group A includes 16 patients randomly selected by an uninformed person and treated with atomoxetine 40 mg for 2 weeks and then increase the dose to 80 mg for six we

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Diagnosis of Parkinson's disease based on examination and history 2) Patients with stage 2-4 of Hoehn and yahr scale; 3) Normal tests (vitamin B12, thyroid, liver, and kidney tests) 4) Levodopa treatment for at least 3 months before the study 5) Ability to walk at least 20 steps without the use of assistive devices

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Freezing of gait in patient with Parkinson. Timepoint: Patients are treated with atomoxetine at a dose of 40 mg for 2 weeks and then increase the dose to 80 mg for six weeks. Method of measurement: The first visit will be on the first day and before starting treatment, determining the FOGQ questionnaire's score, and starting the medication. This questionnaire consists of 6 questions, each of which receives a score of 0 to 4, and the minimum score is 0, and the maximum is 24. The second visit will take place two weeks after the start of treatment, and the third visit will take place 6 weeks after the second visit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Ehsan Mohamadianinejad

Ahvaz University of Medical Sciences

D.R.ramezanirad@gmail.com+98 61 3320 4531

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 5, 2026